A strategy note combining KR Theme ETF Rebalance Flow v1, KOSPI big-figure breakout/pullback patterns, and the KOSPI200 expiry semiconductor squeeze monitor to frame how investors can respond when ETF and program flow drive Korean equities.
On June 12, 2026, foreigners bought KRW 2.72tn of KOSPI shares after 24 straight sessions of selling. But that is only 3.6% of the prior KRW 75.57tn selloff, and the buying was concentrated in Samsung Electronics and SK Hynix.
The first KR Theme ETF Rebalance Flow v1 run flagged Korea theme ETF cap-redistribution pressure. As of June 12, 2026, semiconductor equipment/material names such as Leeno, EO Technics, Soulbrain, DB HiTek, Hanmi Semiconductor, ISC and Wonik IPS screened as redistribution-buy candidates, while SK Hynix, Samsung Electro-Mechanics and LS ELECTRIC appeared on cap-trim watch.
The fuel powering the AI supercycle is changing. It starts with the explosion in token demand created by AI agents, runs through Big Tech's corporate bonds and internal cash as the first funding source, and then opens an entirely new supply channel as mega-IPOs like SpaceX and Anthropic tap the public markets. In a cycle where both demand and money keep extending, the most powerful yet still cheapest asset left is memory and storage. Nomura's price targets — KRW 590,000 for Samsung Electronics and KRW 5,000,000 for SK Hynix — are the signal.
Korean semiconductor equipment stocks surged June 11 as UBS called a WFE supercycle. Samsung and SK Hynix lagged on heavy institutional selling. KOSPI analysis.
KOSPI fell 4.9% on heavy institutional selling while semiconductor equipment names surged. Gigavis hits all five screeners as Korea's top re-rating candidate.
Samsung Biologics, SK Biopharm, Hanmi, Oscotec, Alteogen, ST Pharm. For all six names the 'trigger' that can move the stock is still alive. But 'the catalyst is alive' and 'it's cheap right now' are two completely different statements. Even a great company is a tough new buy if it is already expensive. This is a plain-language follow-up to our earlier bio-sector thesis ('the market rewards stocks where the data is under-priced'), applied to these six names. Bottom line: for fresh money today, SK Biopharm and ST Pharm screen best. Figures are intraday on June 11, 2026 and from company/press sources, so they keep changing.
Samsung Electronics and SK Hynix remain the center of gravity in Korea. But a local screen found 35 Korean companies where FY2026 EPS estimates are up at least 5%, Q1 earnings were positive, and the share price still sits below the 2025 year-end close. This post turns that screen into a Q3 quality watchlist.
KOSPI jumped 7.5% on June 9 as institutions aggressively bought Korean semiconductor stocks after the prior session's circuit breaker. Is it a trend reversal or a dead-cat bounce?